Louis P. Kassa III, MPA, CEO of the Pennsylvania Biotechnology Center (PABC) and Baruch S. Blumberg Institute, has appointed Nick Spring, BSc, DipM, MCIM, a biotech entrepreneur and former executive in the pharmaceutical industry, as the organizations’ first vice president for strategy and commercial development.
Spring has been the PABC’s Entrepreneur in Residence since July of 2024, advising spinout companies from the Blumberg Institute.
“Nick’s working knowledge of the PABC and Blumberg’s commercial and scientific strengths, coupled with his experience in industry and as an entrepreneur, makes him the ideal person for this essential new position,” Kassa said.
Spring’s career includes executive roles at Merck & Co., where he managed global operations in the UK, Europe, Australia and the U.S. He founded and led Topaz Pharmaceuticals through multiple funding rounds to a successful new drug registration and subsequent sale to Sanofi. He was CEO of Reliefband, an FDA-cleared medical device company, where he spearheaded the development and launch of innovative products. He was a senior partner at Alten Calsoft, a software company, where he led the life sciences practice.
Formerly an adjunct professor at the University of Sciences in Philadelphia, Spring serves as an adjudicator for the Life Sciences Management course at the University of Pennsylvania’s Wharton School of Business.
About the Pennsylvania Biotechnology Center (PABC): The PABC uses a highly successful services-based approach to nurture and guide its member companies to success, advance biotechnology and maximize synergies among nonprofit scientists and their commercial colleagues. The PABC has more than 100 member companies and organizations, primarily small to mid-size biotech and life sciences companies. Nearly 60 of those operate on the Doylestown campus, which is home to the Hepatitis B Foundation and Blumberg Institute. The PABC also manages B+labs at Cira Centre, an incubator in Philadelphia with 24 resident companies, in partnership with Brandywine Realty Trust. Please visit our website and follow us on LinkedIn, Instagram, Twitter (@BiotechnologyPa) and Facebook.
Louis P. Kassa III, MPA, CEO of the Pennsylvania Biotechnology Center (PABC) and Baruch S. Blumberg Institute, has appointed Nick Spring, BSc, DipM, MCIM, a biotech entrepreneur and former executive in the pharmaceutical industry, as the organizations’ first vice president for strategy and commercial development.
Spring has been the PABC’s Entrepreneur in Residence since July of 2024, advising spinout companies from the Blumberg Institute.
“Nick’s working knowledge of the PABC and Blumberg’s commercial and scientific strengths, coupled with his experience in industry and as an entrepreneur, makes him the ideal person for this essential new position,” Kassa said.
Spring’s career includes executive roles at Merck & Co., where he managed global operations in the UK, Europe, Australia and the U.S. He founded and led Topaz Pharmaceuticals through multiple funding rounds to a successful new drug registration and subsequent sale to Sanofi. He was CEO of Reliefband, an FDA-cleared medical device company, where he spearheaded the development and launch of innovative products. He was a senior partner at Alten Calsoft, a software company, where he led the life sciences practice.
Formerly an adjunct professor at the University of Sciences in Philadelphia, Spring serves as an adjudicator for the Life Sciences Management course at the University of Pennsylvania’s Wharton School of Business.
About the Pennsylvania Biotechnology Center (PABC): The PABC uses a highly successful services-based approach to nurture and guide its member companies to success, advance biotechnology and maximize synergies among nonprofit scientists and their commercial colleagues. The PABC has more than 100 member companies and organizations, primarily small to mid-size biotech and life sciences companies. Nearly 60 of those operate on the Doylestown campus, which is home to the Hepatitis B Foundation and Blumberg Institute. The PABC also manages B+labs at Cira Centre, an incubator in Philadelphia with 24 resident companies, in partnership with Brandywine Realty Trust. Please visit our website and follow us on LinkedIn, Instagram, Twitter (@BiotechnologyPa) and Facebook.